DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat - PubMed (original) (raw)
. 1999 May 1;162(9):5631-8.
Affiliations
- PMID: 10228047
DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat
E Caselli et al. J Immunol. 1999.
Abstract
Intramuscular immunization of mice with plasmids encoding two transdominant negative mutants of the HIV-1 Tat protein (Tat22 and Tat22/37) elicited a humoral response to wild-type Tat that is comparable to that induced by inoculation of wild-type tat DNA or Tat protein. The percentage of the responders and the Ab titers continued to increase after three additional DNA boosts and pretreatment with bupivacaine at the site of inoculation, without a significant difference (p > 0.05) among the three groups of mice immunized with mutant and wild-type tat genes. By utilizing synthetic peptides representing the amino acid sequence of Tat, one major B cell epitope was defined within the cysteine-rich domain of Tat. Anti-Tat IgG Abs directed against this epitope were found in mice immunized with all tat DNA constructs, whereas different Tat epitopes were detected in mice immunized with the Tat protein. Similarly, IgG2a was the predominant isotype in DNA-immunized mice, with both mutants and wild-type tat genes, as compared with protein immunization, which induced mostly IgG1 and IgG3. Sera from most immunized mice neutralized the effect of extracellular Tat in activating HIV-1 replication. A cellular response was also elicited as indicated by the proliferation of splenocytes when stimulated with wild-type Tat. These results indicate that the wild-type Tat Ag is recognized by Abs and T cells induced by DNA immunization with mutated tat genes, suggesting the possible use of these Tat transdominant mutants, lacking viral trans activation activity and capable of blocking wild-type Tat activity, in the development of an anti-HIV-1 vaccine.
Similar articles
- Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L, Anand KK, Mohankumar KM, Ranga U. Ramakrishna L, et al. J Virol. 2004 Sep;78(17):9174-89. doi: 10.1128/JVI.78.17.9174-9189.2004. J Virol. 2004. PMID: 15308713 Free PMC article. - Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K, Boykins RA, Hewlett IK, Wood OL, Clouse KA, Yamada KM, Dhawan S. Devadas K, et al. Peptides. 2007 Mar;28(3):496-504. doi: 10.1016/j.peptides.2006.11.007. Epub 2006 Dec 22. Peptides. 2007. PMID: 17188401 - Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Zhao J, Voltan R, Peng B, Davis-Warren A, Kalyanaraman VS, Alvord WG, Aldrich K, Bernasconi D, Buttò S, Cafaro A, Ensoli B, Robert-Guroff M. Zhao J, et al. Virology. 2005 Nov 10;342(1):1-12. doi: 10.1016/j.virol.2005.07.016. Epub 2005 Aug 18. Virology. 2005. PMID: 16109434 - Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography.
Serrière J, Dugua JM, Bossus M, Verrier B, Haser R, Gouet P, Guillon C. Serrière J, et al. J Mol Biol. 2011 Jan 7;405(1):33-42. doi: 10.1016/j.jmb.2010.10.033. Epub 2010 Oct 28. J Mol Biol. 2011. PMID: 21035463 Review. - HIV-1 Tat-based vaccines: from basic science to clinical trials.
Fanales-Belasio E, Cafaro A, Cara A, Negri DR, Fiorelli V, Butto S, Moretti S, Maggiorella MT, Baroncelli S, Michelini Z, Tripiciano A, Sernicola L, Scoglio A, Borsetti A, Ridolfi B, Bona R, Ten Haaft P, Macchia I, Leone P, Pavone-Cossut MR, Nappi F, Vardas E, Magnani M, Laguardia E, Caputo A, Titti F, Ensoli B. Fanales-Belasio E, et al. DNA Cell Biol. 2002 Sep;21(9):599-610. doi: 10.1089/104454902760330138. DNA Cell Biol. 2002. PMID: 12396602 Review.
Cited by
- The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile.
Kashi VP, Jacob RA, Shamanna RA, Menon M, Balasiddaiah A, Varghese RK, Bachu M, Ranga U. Kashi VP, et al. PLoS One. 2014 Dec 22;9(12):e114155. doi: 10.1371/journal.pone.0114155. eCollection 2014. PLoS One. 2014. PMID: 25531437 Free PMC article. - Identification of a highly conserved surface on Tat variants.
Mediouni S, Darque A, Ravaux I, Baillat G, Devaux C, Loret EP. Mediouni S, et al. J Biol Chem. 2013 Jun 28;288(26):19072-80. doi: 10.1074/jbc.M113.466011. Epub 2013 May 15. J Biol Chem. 2013. PMID: 23678001 Free PMC article. - What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?
Campbell GR, Loret EP. Campbell GR, et al. Retrovirology. 2009 May 25;6:50. doi: 10.1186/1742-4690-6-50. Retrovirology. 2009. PMID: 19467159 Free PMC article. Review. - Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes.
Voltan R, Castaldello A, Brocca-Cofano E, Altavilla G, Caputo A, Laus M, Sparnacci K, Ensoli B, Spaccasassi S, Ballestri M, Tondelli L. Voltan R, et al. Pharm Res. 2007 Oct;24(10):1870-82. doi: 10.1007/s11095-007-9310-8. Epub 2007 May 3. Pharm Res. 2007. PMID: 17476465
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources